OnCo
companiesCompany

Verastem Oncology

RAS/MAPK-pathway company whose avutometinib + defactinib combination became the first approved treatment for KRAS-mutant low-grade serous ovarian cancer (May 2025).

AVMAPKI FAKZYNJA CO-PACK (RAF/MEK clamp avutometinib plus FAK inhibitor defactinib) received accelerated approval on 8 May 2025 for recurrent KRAS-mutated LGSOC after prior therapy (RAMP 201). Also developing a KRAS G12D inhibitor (VS-7375) and combinations in pancreatic cancer.

Headquarters
Needham, MA, US
Type
biotech · VSTM

Products

1top
ApprovedSmall-molecule RAF/MEK clamp + FAK inhibitor
Avutometinib + defactinib · Avmapki Fakzynja Co-Pack

Avutometinib plus defactinib is the first treatment approved specifically for low-grade serous ovarian cancer, a slow-growing type driven by the RAS pathway.

Connected

9top

cancers

2
Ovarian cancerPancreatic ductal adenocarcinoma

fronts

1
Targeted Therapy

technologies

2
KRAS & RAS inhibitorsSmall-molecule kinase inhibitors

targets

1
KRAS

drugs

1
ApprovedSmall-molecule RAF/MEK clamp + FAK inhibitor
Avutometinib + defactinib · Avmapki Fakzynja Co-Pack

pathways

1
RAS / RAF / MEK / ERK (MAPK)

trials

1
RAMP 201